TickerTalks
Browse all tickers →
TickerTalks›$CGEM
CGCGEM

Cullinan Therapeutics, Inc.

$CGEM·$1.0B·Biotechnology·Healthcare
$14.76-4.4%YTD+46.6%1Y+156.1%
Price updated 7m ago
CGCGEM
$CGEMCullinan Therapeutics, Inc.
$14.76-4.41%0 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $CGEM on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

0X posts · last 7 days
No mention history yet

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $CGEM — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventCooling offAI verdict · as of 2026-09-24

Catching its breath after a run — could pick back up or fade from here.

Cullinan Therapeutics dropped 22% after Zipalertinib Phase 3 REZILIENT3 data — a $1B biotech where the 6-month PFS median benefit is being repriced hard.

CGEM is a small-cap biotech developer with lead program Zipalertinib for EGFR exon 20 insertion NSCLC — Q2 revenue essentially zero (pre-commercial), EPS -$0.81.

  • Multiple set irrelevant (pre-commercial): PE -5.0 (small denominator), PS 0 (no revenue), ROE -53%, D/E 0.006 (essentially unlevered), FCF yield -15.4%.
  • Sept 13 news: Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase — the specific clinical catalyst that then drove -22% intraday drop (data may have been in line with or below expectations).
  • Sept 14 news: Cullinan Therapeutics Analyst/Investor Event.
  • Structural: position 64% of 52-week range, volume multiplier 2.91 (extreme), beta -0.01 (uncorrelated), low float.
  • Recent EPS surprises modest (-1.3%, +10.3%, +3.8%, +18.9%).
  • Consensus 2026 EPS -$3.18 with next-quarter estimate -$0.84.
  • Insider tape: Michaelson sold $173K + M-Exempt — modest distribution.
  • Engineers Gate Manager position increased (Sept 15) — modest institutional accumulation.

Nov 5 Q3 print at -$0.84 EPS is administrative — the actual thesis drivers are Zipalertinib label-expansion progress, any partnership commentary, and cash-and-runway disclosure.

What to watch: Nov 5 Q3 print at -$0.84 EPS — Zipalertinib label-expansion progress commentary, any partnership commentary, and cash-and-runway disclosure given the -15% FCF burn are the multi-quarter thesis tells. Watch for any additional Zipalertinib clinical readouts, and Takeda/AZN peer prints for EGFR exon 20 competitive read.

On the calendar: 2026-11-05

Read the AI verdict on $CGEM

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $CGEM.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver; MRNA's personalized cancer vaccine (melanoma Phase 3 Oct readout) has extended a 137% monthly run. IBB +42% T12M reflects broad RNA-medicine and gene-editing multiple re-rating; GLP-1 pipeline names (ALT, VKTX, KLRA) are the secondary near-term catalyst cohort.

Top industry ETF

$IBBiShares Biotechnology ETF
+23.3%YTD
+47.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-5.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-68.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-15.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-52.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.81$-0.80-1.3%
Q1 2026May 7, 2026$-0.75$-0.84+10.3%
Q4 2025Mar 10, 2026$-0.77$-0.80+3.8%
Q3 2025Nov 6, 2025$-0.77$-0.95+18.9%
Next earningsThu, Nov 5·consensus EPS $-0.84

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-0.81$-38.2M
Q1 FY26$0———$-0.84$-46.0M
Q4 FY25$0———$-0.86$-38.1M
Q3 FY25$0———$-0.86$-36.9M

Forward consensus

5-year forecast · up to 8 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$12.6M$8.8M – $19.1M-$3.18-$3.64 – -$2.807
FY27$47.8M$16.4M – $101.5M-$2.60-$3.10 – -$1.718
FY28$53.1M$37.1M – $80.3M-$3.05-$3.40 – -$2.838
FY29$89.1M$62.3M – $134.8M-$2.96-$4.93 – -$1.806
FY30$256.9M$179.7M – $388.6M-$1.64-$2.73 – -$1.006

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.2.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.56%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-21.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+1.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 44.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today6.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-0.015-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 8Jennifer MichaelsonChief Scientific Officer8.0K sh$173KSellAug 13Jennifer MichaelsonChief Scientific Officer30.0K sh$608KSellJul 6Jennifer MichaelsonChief Scientific Officer8.0K sh$143KSellMay 5Jennifer MichaelsonChief Scientific Officer8.0K sh$117K
+ 12 other (8 awards · 4 exempts) in window

See when $CGEM insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDSep 248-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Cullinan Therapeutics (CGEM) announced on September 24, 2026 plans to share immunology and oncology pipeline updates in Q4 2026, including multi-dose and single target dose regimen data from ongoing Phase 1 clinical trials of CLN-978 in treatment-refractory patients across multiple indications. Additional pipeline milestone disclosures are expected during the quarter. This is a forward-looking clinical data guidance disclosure; Phase 1 data readouts for CLN-978 in collaboration with Taiho are near-term catalysts for this clinical-stage biotech.

8-KPress release / Reg FDSep 148-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Cullinan Therapeutics (CGEM) and partner Taiho announced clinical results on September 13, 2026, with details furnished via attached press release Exhibit 99.1; the specific trial readout is not fully visible in the available excerpt. The announcement was made jointly with Taiho, Cullinan's major oncology development partner. Clinical announcements with a major pharma partner are material potential catalysts for this clinical-stage biotech.

8-KPress release / Reg FDAug 138-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Cullinan Therapeutics (CGEM) and partner Taiho announced on August 12, 2026 that the REZILIENT3 clinical trial — evaluating a therapy for non-small cell lung cancer patients with EGFR exon 20 insertion mutations — met its primary endpoint of progression-free survival at a planned interim analysis. Full results are furnished in the press release Exhibit 99.1. This is a pivotal positive Phase 3 clinical readout, a transformative catalyst that supports a potential regulatory approval path and significantly increases the compound's commercial value.

8-KShareholder voteJun 168-K — Item 5.07: Shareholder vote
8-KPress release / Reg FDJun 108-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
8-KPress release / Reg FDJun 88-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
8-KPress release / Reg FDMay 188-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
S-3ASRAuto-shelf registrationApr 28S-3ASR
+ 11 other (4 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolioglobenewswire.com·1d agoCullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forumglobenewswire.com·4d agoEngineers Gate Manager LP Increases Stock Position in Cullinan Therapeutics, Inc. $CGEMdefenseworld.net·11d agoCullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcriptseekingalpha.com·11d agoCullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancerglobenewswire.com·11d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALT$MRNA$AURA$NWBO$IBRX$SLS$IOVA$CMPS
Voices on X · last 7 days

No standout posts about $CGEM on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport